Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
Part of paid clinical trials in Charlotte, North Carolina.
- Sponsor
- Wake Forest University Health Sciences
- Study ID
- NCT05376592
- Status
- Recruiting
Conditions
- Cachexia
- Pancreas Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
A major complication of pancreatic adenocarcinoma (PDAC) is cancer cachexia (CC) which is a complex syndrome characterized by skeletal muscle mass loss (with or without loss of fat mass) and progressive functional impairment not reversible by conventional nutritional support. It is estimated to occur in over 75% of patients with advanced PDAC, the highest incidence of all solid tumors, and contributes significantly to poor outcomes and mortality. Though there is overlap amongst the pathophysiologic studies evaluating CC in murine models of different tumor types, the high prevalence of CC within gastrointestinal (GI) malignancies and specifically PDAC suggest that dedicated studies evaluating polymorphisms in candidate genes specific to PDAC warrant further evaluation. The collection and analysis of specimens under this study will facilitate the identification and characterization of genomic polymorphisms associated with CC in PDAC patients. Subsequently, this data may help contribute towards diagnostic and therapeutic treatments that may improve patient outcomes.
Key Dates
- Start date
- Jun 17, 2022
- Status verified
- Jan 2026
- Primary completion
- Jan 31, 2031
- Completion
- Jan 31, 2031
Study Design
- Enrollment
- 100 participants (estimated)
Primary Outcome Measure
Cancer cachexia (CC) [ Time Frame: approx. 3 months ]
Central Contacts
- CynDavia McKoy704-355-2000
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | Kunal Kadakia, MD (PRINCIPAL_INVESTIGATOR) |
| Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina | 27103 | Ravi Paluri, MD |
Find similar trials in Charlotte, NC
Related Studies
- Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic CancerPHASE2 · Recruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaPHASE2 · Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatiguePHASE2/PHASE3 · Recruiting · Pfizer · Birmingham, Alabama
- Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerPHASE2 · Recruiting · Loma Linda University · Loma Linda, California